Volition is a leading epigenetics biomarker company, renowned for its proprietary immunoassay approach to profiling cell-free circulating nucleosomes. Our fully quantitative assays have demonstrated significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Our fee-for-service portfolio, Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi), as well as innate immune activation (NETosis). Nu.Q® assays effectively correlate with disease and tumour burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.
Discover more at www.volition.com and join us at the Next Generation Immuno-Oncology Conference to explore how we can support your projects.
.png)
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
.png)
Universal Sequencing Technology Corporation (UST) is a leading NGS biotechnology company based in San Diego and Boston, developer of TELL-SeqTM linked read library preparation technology that enables short read NGS platforms to produce super long read results, proven the best solution for microbial de novo sequencing, metagenomics, human genome phasing and structural variation detection, and AmpliDropTM single cell technology for cost-effective high throughput transcriptomic analyses. UST is poised to lead the next wave of DNA sequencing innovations.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 240+ employees, R&D laboratories of 11000 m2 and 300+ clients and partners all around the world.
Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit www.biocytogen.com
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi.
Learn more at biolog.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
At Olink Proteomics, we revolutionize biomarker discovery with our high-multiplex Proximity Extension Assay technology. Specializing in the human plasma proteome, we provide high-throughput, sensitive, and specific analysis from minimal sample volumes. Our mission is to advance proteomics across various diseases, bridging biomarker workflows from discovery to clinical utility. Trusted in over 1,500 publications, Olink is at the forefront of uncovering vital insights into human health and disease.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
Cellecta, Inc., founded in 2006, is a trusted provider of functional genomic products and services for loss-of-function and gain-of-function phenotypic screening, cell barcoding as well as gene expression and T-cell and B-cell receptor profiling. This includes design and manufacture of CRISPR and RNAi libraries, lentiviral constructs and cell engineering services as well as NGS profiling assays and spatial transcriptomic services for drug target and biomarker discovery and other applications. For more information visit cellecta.com
Precision Antibody prides itself in developing application-specific antibodies with high specificity and sensitivity. In the field of biomarkers, the specificity and sensitivity of reagents are key performance characteristics for a successful assay development necessary for clinical application. With over 20 years of experience and expertise, Precision Antibody (PA) understands these challenges, offering a “one-stop shop” for many clients needing comprehensive application-specific antibody development services, from initial antigen design and immunization to antibody development, characterization, sequencing, and purification. Thanks to our ability to deliver antibodies that work in the intended assay in 60 days, PA has become a preferred vendor for many major pharmaceutical, biotech, and diagnostic companies, including many academic and government institutions, to fulfill their therapeutic and diagnostic needs.
Bioform solutions has developed a robust assay to monitor the cell health of probiotics, regardless of strains or the matrix. Flow cytometry is a single cell analysis tool. It can enumerate bacteria or yeast, alone or in a mix. It is the only way to enumerate heat killed cells (postbiotics) since they won’t grow. CFUs have been used in the industry for decades due to no extra equipment or knowledge needed, but the data has a 30-50% variability which leads to large questions about its accuracy. It also can only see cells that can grow in a particular media, so mixed strain probiotics can be very problematic. When the cells become stressed out due to processing and packaging, they can become viable but not culturable (VBNC), which means they won’t grow in a CFU assay. Flow cytometry gets around these issues by viewing all of the cells in a product, quickly and accurately with a CV <5%. Flow cytometry takes ~15 minutes whereas the CFU assay takes 3 days. This allows quick decisions to be made as a product is being formulated as well as determining the stability of the products.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Altis Biosystems has developed a series of in vitro human intestinal cell models called Repligut® Systems which are developed from the different intestine regions and can be used for compound screening, disease modelling, toxicity, efficacy, host-pathogen interactions and basic research studies. We are proud to have industry-leading scientists on our team who share a passion for creating high-throughput, scalable, and translatable products and services to support research to improve gut health.
For over 55 years, INFORS HT has been developing and producing high-tech incubation shakers, bioreactors, and bioprocess control software for cell culture and microbial applications in biotechnology. In keeping with our company creed— “We firmly believe you can make anything better”— we commit ourselves each day to simplifying our customers’ workflows using the most modern technologies available.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
Biological Dynamics, Inc. is a leader in exosome-isolation technology committed to improving global health outcomes by identifying early-stage diseases. Its Verita™ platform offers a simple and automated workflow to enrich exosomes, powering advanced detection tests for the most challenging diseases. Biological Dynamics’ ExoVita™ assays utilize the Verita platform to enable reliable surveillance and early cancer detection to help enhance and extend lives. The Company operates a CAP-accredited, CLIA-certified clinical laboratory in San Diego, California.
Zymo Research is a globally established biotechnology company and industry leader in the fields of microbiomics, epigenetics, and the emerging Next-Gen Sequencing space. From providing technologically advanced products to validated NGS services, everything is driven by the fundamental belief that "the beauty of science is to make things simple.
Established in 1998 by Dr. Yousef Haj-Ahmad, Norgen Biotek is a biotechnology leader, housed in a 24,000 sq ft facility in Thorold, Ontario. With ISO 9001, ISO 13485, and ISO 15189 certifications, we excel in innovative sample collection, preparation, and detection products. Our commitment to continuous improvement extends to fostering partnerships and supporting scientific advancement globally. Beyond products, we champion education, contributing to the betterment of our community
SageMedic Corp, headquartered in California, is revolutionizing cancer diagnostics with a scalable platform that transcends the limitations of genomic testing, delivering results within just one week. Our pioneering OncotestTM harnesses a machine learning enabled 3D live cell sensitivity and resistance assay, empowering oncologists to make informed treatment decisions for improved patient outcomes through functional tumor profiling.
Unlike traditional methods that rely on slow and often unreliable tumor cell proliferation, the Oncotest™ is both faster and more dependable. Our vision is to elevate personalized cancer therapy to the forefront, fostering hope and enhancing the quality of life for each patient. At SageMedic Corp, we are committed to making tailored therapy the new standard in cancer care.
GemPharmatech is a global company providing high-quality products and model systems for discovery, testing, development and production of new drugs and therapeutic solutions. GemPharmatech is one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners across the world. With advance gene editing technology, GemPharmatech has created and produced a large collection of over 14,000 transgenic mouse models for therapeutic applications.
